ClinicalTrials.gg
Active, not recruitingNCT06555744Updated May 7, 2026

A Study of ZW191 in Participants With Solid Tumors

A Phase 1 interventional study of ZW191 in Advanced Solid Tumors, sponsored by Zymeworks BC Inc.. Active, not recruiting at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Zymeworks BC Inc. (part of Zymeworks) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.

Read the detailed description

Part 1 of the study will evaluate the safety and tolerability of ZW191. Part 2 of the study will further evaluate safety and explore the potential anti-tumor activity of ZW191.

02

Conditions studied

  • Advanced Solid Tumors

Browse trials for

Keywords

  • Advanced or Metastatic Cancers
  • ADC
  • Folate alpha receptor
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 145 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Zymeworks BC Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or disease.
  • per v1.1.
  • (ECOG) Performance Status score of 0 or 1.
  • Adequate cardiac function: Cardiac left ventricular function, as defined by (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
  • Other adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Known additional that is progressing or requires active treatment or may interfere with study endpoints.
  • Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of .
  • Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
  • Severe chronic or active infections (including known active SARS-CoV-2 infection) requiring systemic therapy, including antibacterial, antifungal, or antiviral therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (estimated)

Study arms

  • Experimental
    ZW191

    Drug: ZW191

Interventions

  • DrugZW191

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs; Part 1)

    Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW191

    Time frame: Up to 3 weeks

  2. Incidence of adverse events (AEs; Parts 1 and 2)

    Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)

    Time frame: Up to approximately 2 years

  3. Incidence of clinical laboratory abnormalities (Parts 1 and 2)

    Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: Up to approximately 2 years

  4. Confirmed objective response rate (Part 2)

    Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Confirmed objective response rate (Part 1)

    Number of participants who achieved a best overall response of either confirmed CR or PR during treatment according to RECIST v1.1

    Time frame: Up to approximately 2 years

  2. Clinical benefit rate (Parts 1 and 2)

    Number of participants who achieved a best response of CR, PR, non-CR/non-progressive disease (PD), or stable disease (SD) lasting at least 180 days per RECIST v1.1

    Time frame: Up to approximately 2 years

  3. Duration of response (DOR; Part 2)

    The time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death within 30 days of last dose of study treatment from any cause. Only participants who achieve a confirmed response will be included in the analysis

    Time frame: Up to approximately 2 years

  4. Disease control rate (DCR; Part 2)

    Number of participants who achieved a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or SD during treatment per RECIST v1.1

    Time frame: Up to approximately 2 years

  5. Progression-free survival (PFS; Part 2)

    The time from the first dose of study treatment to the date of first documented PD per RECIST v1.1 or death from any cause

    Time frame: Up to approximately 2 years

  6. Best overall response (BOR; Part 2)

    Time frame: Up to approximately 2 years

  7. Serum or plasma concentration and PK parameters of ZW191 (Parts 1 and 2)

    Maximum serum concentration and trough concentration of ZW191

    Time frame: Up to approximately 2 years

  8. Incidence of anti-drug antibodies (ADAs; Parts 1 and 2)

    Number of participants who develop ADAs

    Time frame: Up to approximately 2 years

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 26 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 15, 2024
StartActual
Oct 30, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06555744
Lead sponsor
Zymeworks BC Inc.
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Oct 30, 2024
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
May 7, 2026

Study contacts

Maggie Weinstein, MD, PhD, MPH
study director · Zymeworks BC Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion